Lactulose, Disaccharides and Colonic Flora

SummaryLactulose is one of the most frequently utilised agents in the treatment of constipation and hepatic encephalopathy because of its efficacy and good safety profile. The key to understanding the possible modes of action by which lactulose achieves its therapeutic effects in these disorders lies in certain pharmacological phenomena: (a) lactulose is a synthetic disaccharide that does not occur naturally; (b) there is no disaccharidase on the microvillus membrane of enterocytes in the human small intestine that hydrolyses lactulose; and (c) lactulose is not absorbed from the small intestine. Thus, the primary site of action is the colon in which lactulose is readily fermented by the colonic bacterial flora with the production of short-chain fatty acids and various gases. The purpose of this review is to focus on some pertinent basic aspects of the clinical pharmacology of lactulose and to discuss the possible mechanisms by which lactulose benefits patients with constipation and hepatic encephalopathy.

• Publication year

  1997

• Venue

  Drugs

• Publication date

  1997-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2165/00003495-199753060-00003PMID 9179525PMCID 7100287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man

  2006cited by this paper
• Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis.

  1995cited by this paper
• Colonic lactate metabolism andd-lactic acidosis

  1995cited by this paper
• Kinetic studies on the metabolism of short-chain fatty acids and glucose by isolated rat colonocytes.

  1994cited by this paper
• Fecal lactate and short bowel syndrome

  1994cited by this paper
• Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H2 criteria.

  1993cited by this paper
• Can diarrhea induced by lactulose be reduced by prolonged ingestion of lactulose?

  1993cited by this paper
• Lactulose in the Management of Constipation: A Current Review

  1992cited by this paper
• The colon in carbohydrate malabsorption: short-chain fatty acids, pH, and osmotic diarrhoea.

  1992cited by this paper
• Portal and peripheral blood short chain fatty acid concentrations after caecal lactulose instillation at surgery.

  1992cited by this paper
• The effect of oral‐administered lactulose on colonic nitrogen metabolism and excretion

  1992cited by this paper
• Serum levels of short‐chain fatty acids in cirrhosis and hepatic coma

  1991cited by this paper
• The control and consequences of bacterial fermentation in the human colon.

  1991cited by this paper
• Fermentation to short-chain fatty acids and lactate in human faecal batch cultures. Intra- and inter-individual variations versus variations caused by changes in fermented saccharides.

  1991cited by this paper
• The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose.

  1990cited by this paper
• Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.

  1990cited by this paper
• Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose.

  1989cited by this paper
• Short-chain fatty acid production from mono- and disaccharides in a fecal incubation system: implications for colonic fermentation of dietary fiber in humans.

  1988cited by this paper
• Lactulose detoxifies in vitro short-chain fatty acid production in colonic contents induced by blood: implications for hepatic coma.

  1988cited by this paper
• Systemic availability of propionate and acetate in liver cirrhosis.

  1988cited by this paper
• Degradation of amino acids to short-chain fatty acids in humans. An in vitro study.

  1988cited by this paper
• Short chain fatty acids in human large intestine, portal, hepatic and venous blood.

  1987cited by this paper
• Protein origin of the volatile fatty acids isobutyrate and isovalerate in human stool.

  1987cited by this paper
• Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin.

  1987cited by this paper
• Protein origin of the volatile fatty acids isobutyrate and isovalerate in human stool.

  1987cited by this paper
• Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study).

  1985cited by this paper
• The contribution of the large intestine to energy supplies in man.

  1984cited by this paper
• Colonic Compensation in Transmissible Gastroenteritis of Swine

  1984cited by this paper
• The mechanism of hepatic coma

  1981cited by this paper
• Conservation of mannitol, lactulose, and raffinose by the human colon.

  1981cited by this paper
• Role of pH in production of hydrogen from carbohydrates by colonic bacterial flora. Studies in vivo and in vitro.

  1981cited by this paper
• Absorption of short-chain fatty acids by the colon.

  1980cited by this paper
• Regional Cerebral Na+K+ ATPase Activity following Octanoate Administration

  1980cited by this paper
• Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.

  1980cited by this paper
• Mechanism of action of dietary fibre in the human colon

  1980cited by this paper
• The effect of lactulose on urea metabolism and nitrogen excretion in cirrhotic patients

  1979cited by this paper
• Two sistes with isovaleric acidaemia, multiple attacks of ketoacidosis and normal development

  1979cited by this paper
• The effect of lactulose on urea metabolism and nitrogen excretion in cirrhotic patients.

  1979cited by this paper
• Short chain fatty acid absorption by the human large intestine.

  1978cited by this paper
• Effect of lactulose on ammonia production in a fecal incubation system.

  1978cited by this paper
• Simple, rapid method for determination of propionic acid and other short-chain fatty acids in serum.

  1978cited by this paper
• Capacity of the human colon to absorb fluid.

  1978cited by this paper
• Plasma short-chain fatty acids in fulminant hepatic failure.

  1977cited by this paper
• Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

  1977cited by this paper
• Propionic acidemia and anorectal anomalies in three siblings.

  1977cited by this paper
• Intraluminal pressures during perfusion of the human colon in situ.

  1976cited by this paper
• Generation of ammonia from non-urea sources in a faecal incubation system.

  1976cited by this paper
• Quantitative measurement of lactose absorption.

  1976cited by this paper
• Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device

  1974cited by this paper
• The effect of lactulose on the faecal flora of patients with hepatic encephalopathy.

  1974cited by this paper
• Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma.

  1974cited by this paper
• Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma.

  1974cited by this paper
• Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids.

  1973cited by this paper
• The contribution of the colon to electrolyte and water conservation in man.

  1973cited by this paper
• Use of pulmonary hydrogen (H 2 ) measurements to quantitate carbohydrate absorption. Study of partially gastrectomized patients.

  1972cited by this paper
• Faecal ammonia and pH during lactulose administration in man: comparison with other cathartics

  1972cited by this paper
• Absorption of lactulose in man.

  1972cited by this paper
• Role of the small bowel and colon in lactose-induced diarrhea.

  1971cited by this paper
• Fecal acidorrhea.

  1971cited by this paper
• Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy.

  1970cited by this paper
• Transfer of medium chain fatty acids from blood to spinal fluid in patients with cirrhosis.

  1970cited by this paper
• Effects of lactulose and Lactobacillus acidophilus on the fecal flora.

  1970cited by this paper
• Wrong idea, good results (the lactulose story).

  1969cited by this paper
• A new method for evaluation of portasystemic shunting. The rectal octanoate tolerance test.

  1969cited by this paper
• Propionicacidemia, a New Inborn Error of Metabolism

  1968cited by this paper
• THE MECHANISM OF DIARRHOEA IN CONGENITAL DISACCHARIDE MALABSORPTION

  1968cited by this paper
• Short chain fatty acid inhibition of rat brain Na-K adenosine triphosphatase.

  1968cited by this paper
• SHORT CHAIN FATTY ACID INHIBITION OF RAT BRAIN Na‐K ADENOSINE TRIPHOSPHATASEI

  1968cited by this paper
• Isovaleric acidemia. Clinical features of a new genetic defect of leucine metabolism.

  1967cited by this paper
• Treatment of chronic portal-systemic encephalopathy with lactulose.

  1966cited by this paper
• ACQUIRED MILK INTOLERANCE IN THE ADULT CAUSED BY LACTOSE MALABSORPTION DUE TO A SELECTIVE DEFICIENCY OF INTESTINAL LACTASE ACTIVITY.

  1965cited by this paper
• [GAS CHROMATOGRAPHIC DETERMINATION OF PLASMA SHORT CHAIN FATTY ACIDS IN DISEASES OF THE LIVER].

  1964cited by this paper
• Diarrhoea Caused by Deficiency of Sugar Splitting Enzymes. I

  1960cited by this paper
• A study on the narcotic action of the short chain fatty acids.

  1956cited by this paper
• Effects of fatty acid anions on the electroencephalogram of unanesthetized rabbits.

  1956cited by this paper

• Exploring the Impact of Click Chemistry on Carbohydrate Derivatives and their Biological Properties

  2025cites this paper
• Abnormal Blood Bacteriome, Gut Dysbiosis, and Progression to Severe Dengue Disease

  2022cites this paper
• Comparison of diet, lactulose, and metronidazole combinations in the control of pre‐surgical clinical signs in dogs with congenital extrahepatic portosystemic shunts

  2022cites this paper
• Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel.

  2022cites this paper
• Gut permeability and its clinical relevance in schizophrenia

  2022cites this paper
• A New Extracellular β-Galactosidase Producing Kluyveromyces sp. PCH397 from Yak Milk and Its Applications for Lactose Hydrolysis and Prebiotics Synthesis

  2021cites this paper
• Novel Agents in the Management of Hepatic Encephalopathy: A Review

  2021cites this paper
• Development of Personalized Nutrition: Applications in Lactose Intolerance Diagnosis and Management

  2021cites this paper
• Lactulose-induced pneumatosis intestinalis following colonoscopy: a case report

  2021cites this paper
• Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease

  2021cites this paper
• Low-Dose Lactulose as a Prebiotic for Improved Gut Health and Enhanced Mineral Absorption

  2021influential citation
• Sarcopenia secundaria en la encefalopatía hepática: Implicaciones para el seguimiento nutricional

  2020cites this paper
• Functional screening of human faecal microbiome metagenome library for glycoside hydrolase enzymes

  2020cites this paper
• Prebiotics, Synbiotics, and Colonic Foods

  2020cites this paper
• Recent trends and challenges on carbohydrate-based molecular scaffolding: general consideration toward impact of carbohydrates in drug discovery and development

  2020cites this paper
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose

  2019cites this paper
• Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial

  2019cites this paper
• Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation.

  2019cites this paper
• UCC118 supplementation reduces exercise‐induced gastrointestinal permeability and remodels the gut microbiome in healthy humans

  2019cites this paper
• Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota diversity in healthy dogs

  2019cites this paper
• Pneumatosis coli after partial ligation of congenital portosystemic shunt in a dog

  2018cites this paper
• Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED

  2018cites this paper
• A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans

  2018cites this paper
• Lactulose efficacy in reduction of nitrogen products, blood potassium and fluid overload in patients with end-stage renal failure.

  2017cites this paper
• Role of Rifaximin for the Treatment of Hepatic Encephalopathy in Chronic Liver Disease

  2017cites this paper
• The Human Microbiome and Understanding the 16S rRNA Gene in Translational Nursing Science

  2017cites this paper
• Health Implications of Fructose Consumption in Humans

  2017cites this paper
• The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial

  2016cites this paper
• Lactose-Derived Nondigestible Oligosaccharides and Other High Added-Value Products

  2016cites this paper
• Carbohydrate-Based Therapeutics

  2016cites this paper
• Production of Lactulose by Biological Methods and Its Application

  2016cites this paper
• Hepatic encephalopathy

  2016cites this paper
• Gut microbiota: its role in hepatic encephalopathy.

  2015cites this paper
• The potential of resistant starch as a prebiotic

  2015cites this paper
• Central nervous system and pulmonary complications of end‐stage liver disease

  2015cites this paper
• Management of overt hepatic encephalopathy.

  2015cites this paper
• Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function.

  2015cites this paper
• Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.

  2014cites this paper
• Functional Foods and Nutraceuticals: Potential Role in Human Health

  2014cites this paper
• Effect of prebiotics on lyzosymic activity of the Bacillus genus bacteria

  2013cites this paper
• Disaccharides in the treatment of hepatic encephalopathy

  2013cites this paper
• Lactose isomerization into lactulose in an electro-activation reactor and high-performance liquid chromatography (HPLC) monitoring of the process

  2013cites this paper
• Probiotic as a Novel Treatment Strategy Against Liver Disease

  2013cites this paper
• Carbohydrate based potential chemotherapeutic agents: recent developments and their scope in future drug discovery.

  2012cites this paper
• Agents that act luminally to treat diarrhoea and constipation

  2012cites this paper
• Application of the BRAFO tiered approach for benefit-risk assessment to case studies on heat processing contaminants.

  2012cites this paper
• Benefit Risk Analysis for Foods (BRAFO): Qualitative and Quantitative Comparison of Human Health Risks and Benefits of Foods and Food Components

  2012cites this paper
• Применение комбинированного энтеросорбента в комплексной терапии атопического дерматита у детей

  2011cites this paper
• Prophylaxis of hepatic encephalopathy in acute variceal bleed: A randomized controlled trial of lactulose versus no lactulose

  2011cites this paper
• A literature review of two laxatives: lactulose and polyethylene glycol.

  2011cites this paper
• I NGESTION OF T OXIC S UBSTANCES BY C HILDREN

  2011cites this paper
• Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis

  2011cites this paper
• LIFELAX - diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial.

  2010cites this paper
• Current and emerging strategies for treating hepatic encephalopathy.

  2010cites this paper
• Pharmacotherapy for Hepatic Encephalopathy

  2010cites this paper
• Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

  2009cites this paper
• Portal hypertension and its complications.

  2008cites this paper
• Genomics can advance the potential for probiotic cultures to improve liver and overall health.

  2008cites this paper
• Probiotics and Liver Disease

  2008cites this paper
• Effects of therapeutic doses of lactulose vs. polyethylene glycol on isotopic colonic transit

  2008cites this paper
• A novel endovascular adjustable polytetrafluoroethylene-covered stent for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

  2007cites this paper
• Cancer chemopreventive effects of lactic acid bacteria.

  2007cites this paper
• Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

  2007cites this paper
• Fructose Malabsorption May Be Gender Dependent and Fails to Show Compensation by Colonic Adaptation

  2007cites this paper
• Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy

  2006cites this paper
• [Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists].

  2006cites this paper
• Treatment of hepatic encephalopathy.

  2005cites this paper
• Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

  2005cites this paper
• Chronic Systemic Endotoxin Exposure: An Animal Model in Experimental Hepatic Encephalopathy

  2005cites this paper
• Reduced Stents and Stent-Grafts for the Management of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation

  2005cites this paper
• Use of prebiotics for inflammatory bowel disease.

  2005cites this paper
• Redefining lactose as a conditional prebiotic.

  2004cites this paper
• Prospective, randomized, parallel‐group trial to evaluate the effects of lactulose and polyethylene glycol‐4000 on colonic flora in chronic idiopathic constipation

  2004cites this paper
• Gut flora‐based therapy in liver disease? The liver cares about the gut

  2004cites this paper
• TIPS-related hepatic encephalopathy: management options with novel endovascular techniques.

  2004cites this paper
• The Role of Colonic Microbiota in Lactose Intolerance

  2004cites this paper
• Failure to improve parameters of lactose maldigestion using the multiprobiotic product VSL3 in lactose maldigesters: a pilot study.

  2004cites this paper
• Effects of lactulose on intestinal endotoxin and bacterial translocation in cirrhotic rats.

  2003cites this paper
• Lactulose reduces intracolonic acetaldehyde concentration and ethanol elimination rate in rats.

  2003cites this paper
• Differential therapy of constipation--a review.

  2003cites this paper
• C-reactive protein and antibacterial activity in blood plasma of colostrum-fed calves and the effect of lactulose.

  2003cites this paper
• Probiotics can treat hepatic encephalopathy.

  2003cites this paper
• Nutritional advantages of probiotics and prebiotics.

  2002cites this paper
• Non-polyol low-digestible carbohydrates: food applications and functional benefits.

  2001cites this paper
• n-Butyrate Rectal Transport in Cirrhotic Patients

  2001cites this paper
• Hepatic encephalopathy

  2001cites this paper
• Lactulose-induced pneumatosis intestinalis and pneumoperitoneum.

  2001cites this paper
• Tolerance to low-digestible carbohydrates: symptomatology and methods.

  2001cites this paper
• Brain edema and portal‐systemic encephalopathy

  2000cites this paper
• Ingestion of toxic substances by children.

  2000cites this paper
• [Dietary and medicamentous therapy of chronic constipation].

  1999cites this paper